Blueprint Medicines Corp BPMC
We take great care to ensure that the data presented and summarized in this overview for Blueprint Medicines Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BPMC
View all-
Black Rock Inc. New York, NY6.45MShares$660 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.31MShares$646 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.25MShares$640 Million0.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$427 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.5MShares$256 Million6.2% of portfolio
-
State Street Corp Boston, MA2.19MShares$224 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V81.86MShares$191 Million0.2% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.71MShares$175 Million0.44% of portfolio
-
Geode Capital Management, LLC Boston, MA1.37MShares$140 Million0.01% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ1.32MShares$135 Million0.41% of portfolio
Latest Institutional Activity in BPMC
Top Purchases
Top Sells
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BPMC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,850
-2.58%
|
$408,100
$106.86 P/Share
|
May 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
5,856
-15.24%
|
$620,736
$106.89 P/Share
|
May 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,856
+12.47%
|
$228,384
$39.6 P/Share
|
May 08
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
28,181
+14.36%
|
$140,905
$5.34 P/Share
|
May 02
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-17.46%
|
$1,050,000
$105.0 P/Share
|
May 02
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.86%
|
$360,000
$36.05 P/Share
|
May 02
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,834
-10.95%
|
$188,902
$103.88 P/Share
|
May 02
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,834
+9.87%
|
$99,036
$54.13 P/Share
|
Mar 28
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-9.56%
|
$475,000
$95.0 P/Share
|
Mar 28
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.73%
|
$180,000
$36.05 P/Share
|
Mar 20
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
25,073
-2.62%
|
$2,181,351
$87.33 P/Share
|
Mar 20
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
25,073
+6.02%
|
$200,584
$8.44 P/Share
|
Mar 15
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,734
-4.14%
|
$1,208,592
$88.06 P/Share
|
Mar 15
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.57%
|
$180,000
$36.05 P/Share
|
Mar 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
4,549
-8.36%
|
$400,312
$88.19 P/Share
|
Mar 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+4.11%
|
$24,000
$15.01 P/Share
|
Mar 13
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,023
-9.74%
|
$722,070
$90.22 P/Share
|
Mar 13
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,747
+2.01%
|
$19,217
$11.91 P/Share
|
Mar 07
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
11,033
-6.27%
|
$992,970
$90.69 P/Share
|
Mar 07
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,934
-6.68%
|
$264,060
$90.69 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 186K shares |
---|---|
Exercise of conversion of derivative security | 209K shares |
Open market or private sale | 273K shares |
---|